Tort Reform Likely To Move Up PhRMA Priority List

The continued fallout from the Vioxx withdrawal is likely to make tort reform a higher priority for the Pharmaceutical Research & Manufacturers of America heading into 2005

More from Archive

More from Pink Sheet